Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Cereb Blood Flow Metab ; 38(8): 1327-1338, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-28952904

RESUMO

Many preclinical treatment strategies for stroke have failed when tested in human trials. Although the reasons for these translation failures are multifactorial, one potential concern is the statistical analysis of the preclinical data. One way to rigorously evaluate new therapies is to use an intention-to-treat analysis in preclinical studies. Therefore, in this study, we set out to evaluate the treatment efficacy of a potential clinically relevant therapeutic agent for stroke, i.e., anti-Nogo-A immunotherapy, using an intention-to-treat analysis. Adult rats were trained on the skilled forelimb reaching task and subsequently underwent an ischemic stroke. Nine weeks later, the rats either received intracerebroventricular anti-Nogo-A antibody, control antibody, or no treatment. Skilled reaching performance was assessed by a non-linear model using both an intention-to-treat and per-protocol analysis. Following testing, dendritic complexity was evaluated in the contralesional and perilesional sensorimotor cortex. Both intention-to-treat and per-protocol analysis showed that anti-Nogo-A immunotherapy resulted in statistically significant improved recovery on the skilled forelimb reaching task, although treatment effect was less (though statistically significant) in the intention-to-treat group. Improved functional performance was not shown to be associated with dendritic changes. In conclusion, this study provides evidence for the importance of using intention-to-treat paradigms in testing preclinical therapeutic strategies.


Assuntos
Anticorpos/uso terapêutico , Imunoterapia , Proteínas Nogo/antagonistas & inibidores , Acidente Vascular Cerebral/terapia , Animais , Dendritos/efeitos dos fármacos , Dendritos/patologia , Avaliação Pré-Clínica de Medicamentos , Imunoterapia/métodos , Análise de Intenção de Tratamento , Masculino , Córtex Motor/efeitos dos fármacos , Córtex Motor/patologia , Córtex Motor/fisiopatologia , Ratos , Ratos Long-Evans , Recuperação de Função Fisiológica/efeitos dos fármacos , Acidente Vascular Cerebral/patologia , Acidente Vascular Cerebral/fisiopatologia , Resultado do Tratamento
2.
Brain Res ; 1111(1): 176-86, 2006 Sep 21.
Artigo em Inglês | MEDLINE | ID: mdl-16920088

RESUMO

Clinical and laboratory studies have suggested that amphetamine treatment when paired with rehabilitation results in improved recovery of function after stroke or traumatic brain injury. In the present study, we investigated whether new anatomical pathways developed in association with improved motor function after brain damage and amphetamine treatment linked with rehabilitation. Following a unilateral sensorimotor cortex lesion in the adult rat, amphetamine (2 mg/kg) was administered in conjunction with physiotherapy sessions on postoperative days two and five. Physiotherapy was continued twice daily for the first 3 weeks after injury, and then once daily until week six. Performance on skilled forelimb reaching and ladder rung walking was used to assess motor improvement. Our results show that animals with sensorimotor cortical lesions receiving amphetamine treatment linked with rehabilitation had significant improvement in both tasks. Neuroanatomical tracing of efferent pathways from the opposite, non-damaged cortex resulted in the novel finding that amphetamine treatment linked with rehabilitation, significantly increased axonal growth in the deafferented basilar pontine nuclei. These results support the notion that pharmacological interventions paired with rehabilitation can enhance neuronal plasticity and thereby improve functional recovery after CNS injury.


Assuntos
Anfetamina/farmacologia , Lesões Encefálicas/tratamento farmacológico , Lesões Encefálicas/reabilitação , Córtex Motor/efeitos dos fármacos , Plasticidade Neuronal/efeitos dos fármacos , Recuperação de Função Fisiológica/efeitos dos fármacos , Anfetamina/uso terapêutico , Animais , Axônios/efeitos dos fármacos , Axônios/fisiologia , Axônios/ultraestrutura , Biotina/análogos & derivados , Lesões Encefálicas/fisiopatologia , Estimulantes do Sistema Nervoso Central/farmacologia , Estimulantes do Sistema Nervoso Central/uso terapêutico , Dextranos , Modelos Animais de Doenças , Vias Eferentes/efeitos dos fármacos , Vias Eferentes/fisiologia , Cones de Crescimento/efeitos dos fármacos , Cones de Crescimento/fisiologia , Cones de Crescimento/ultraestrutura , Masculino , Córtex Motor/lesões , Córtex Motor/fisiopatologia , Regeneração Nervosa/efeitos dos fármacos , Regeneração Nervosa/fisiologia , Plasticidade Neuronal/fisiologia , Paresia/tratamento farmacológico , Paresia/fisiopatologia , Paresia/reabilitação , Modalidades de Fisioterapia , Tratos Piramidais/efeitos dos fármacos , Tratos Piramidais/fisiologia , Ratos , Ratos Long-Evans , Recuperação de Função Fisiológica/fisiologia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA